Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO DELAY IN PUBLICATION OF 2024 ANNUAL RESULTS AND CONTINUED SUSPENSION OF TRADING

This announcement is made by China Tianrui Group Cement Company Limited (the "**Company**", together with its subsidiaries, collectively referred to as the "**Group**") pursuant to the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

Reference is made to the announcement of the Company dated 31 March 2025 regarding, among other things, the delay in publication of the 2024 Annual Results Announcement and the suspension of trading in the shares of the Company on the Stock Exchange with effect from 9:00 a.m. on 1 April 2025 (the "**Announcement**"). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

REASONS FOR THE DELAY IN PUBLICATION OF 2024 ANNUAL RESULTS

The Company would like to provide additional information about the reasons for the delay in the publication of the 2024 Annual Results as set out below.

The Company is actively assisting the auditors (the "**Auditors**") to collect information and documents for the Auditors to complete its audit work in relation to the 2024 Annual Results including but not limited to obtaining certain information from previous auditors, certain audit procedures on the opening balances and prepayments to suppliers. In addition, certain confirmations for audit purpose have not yet been received by the Auditors. The abovementioned information and documents are for the Auditors to:

- (1) understand the basis of certain consolidation adjustments brought forward from prior years, of which certain of them are related to audit adjustments made by the previous auditors, and some of which may have consequential financial effects on the consolidated financial statement of the Company for the year ended 31 December 2024;
- (2) verify certain opening balances, including but not limited to, confirming the amount of prepayments made to suppliers as at 31 December 2023;
- (3) conduct interview with key suppliers, check the subsequent utilization and/or settlements of the prepayments to suppliers, and assess the recoverability of such prepayments; and
- (4) obtain confirmations from certain third parties, including among others, banks, for audit purposes.

The Company is working closely with its Auditors with a view to resolving the outstanding matters and completing the audit of the 2024 Annual Results as soon as practicable. As at the date of this announcement and taking into account the current situation, it is expected that the 2024 Annual Results will be published by 30 May 2025, subject to completion of all audit work as agreed with the auditors.

CONTINUED SUSPENSION OF TRADING

Trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 1 April 2025 and will continue to be suspended pending the publication of the 2024 Annual Results by the Company.

Shareholders of the Company and potential investors are advised to exercise caution in dealing in the securities of the Company.

By order of the Board China Tianrui Group Cement Company Limited Li Liufa Chairman

Hong Kong, 29 April 2025

As at the date of this announcement, the Board consists of executive Directors, Ms. Li Fengluan, Mr. Ding Jifeng, Mr. Li Jiangming and Mr. Jin Mingjie; Chairman and nonexecutive Director, Mr. Li Liufa; and Independent Non-executive Directors, Mr. Kong Xiangzhong and Mr. Mak Tin Sang.